DK0767634T3 - Mikrokapsler til administration af neuroaktive midler - Google Patents

Mikrokapsler til administration af neuroaktive midler

Info

Publication number
DK0767634T3
DK0767634T3 DK95924078T DK95924078T DK0767634T3 DK 0767634 T3 DK0767634 T3 DK 0767634T3 DK 95924078 T DK95924078 T DK 95924078T DK 95924078 T DK95924078 T DK 95924078T DK 0767634 T3 DK0767634 T3 DK 0767634T3
Authority
DK
Denmark
Prior art keywords
mum
microspheres
microcapsules
administration
nervous system
Prior art date
Application number
DK95924078T
Other languages
English (en)
Inventor
Thomas R Tice
David W Mason
Amanda Mcrae-Mcfarland
Annica B Dahlstrom
Deborah L Dillon
Original Assignee
Southern Res Inst
Mcrae Mcfarland Amanda
Annica B Dahlstrom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst, Mcrae Mcfarland Amanda, Annica B Dahlstrom filed Critical Southern Res Inst
Application granted granted Critical
Publication of DK0767634T3 publication Critical patent/DK0767634T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5063Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068Cell membranes or bacterial membranes enclosing drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery
    • Y10S977/907Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
DK95924078T 1994-06-29 1995-06-28 Mikrokapsler til administration af neuroaktive midler DK0767634T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/268,177 US6517859B1 (en) 1990-05-16 1994-06-29 Microcapsules for administration of neuroactive agents
PCT/US1995/008123 WO1996000537A1 (en) 1994-06-29 1995-06-28 Microcapsules for administration of neuroactive agents

Publications (1)

Publication Number Publication Date
DK0767634T3 true DK0767634T3 (da) 2004-07-19

Family

ID=23021810

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95924078T DK0767634T3 (da) 1994-06-29 1995-06-28 Mikrokapsler til administration af neuroaktive midler

Country Status (8)

Country Link
US (2) US6517859B1 (da)
EP (1) EP0767634B1 (da)
JP (1) JPH10506373A (da)
AT (1) ATE261278T1 (da)
DE (1) DE69532673T2 (da)
DK (1) DK0767634T3 (da)
ES (1) ES2217281T3 (da)
WO (1) WO1996000537A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
US20080121141A1 (en) * 2006-11-16 2008-05-29 Haggquist Gregory W Exothermic-enhanced articles and methods for making the same
EP2286893B1 (en) * 2002-06-12 2013-06-05 Cocona, Inc. Encapsulated active particles and methods for making and using the same
PL1610791T3 (pl) 2003-03-31 2011-07-29 Titan Pharmaceuticals Inc Wszczepialne urządzenie polimerowe do przedłużonego uwalniania agonisty dopaminy
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2006097725A2 (en) * 2005-03-15 2006-09-21 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20070191272A1 (en) * 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
EP2520611B1 (en) * 2006-05-09 2017-06-21 Cocona, Inc. Method for producing a water-proof breathable membrane
CA2666246C (en) 2006-10-12 2013-12-31 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008122044A2 (en) * 2007-04-02 2008-10-09 Georgia Tech Research Corporation Implantable device for communicating with biological tissue
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2009010842A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
KR20100058541A (ko) * 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
CA2736729A1 (en) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
ES2730800T3 (es) * 2009-02-03 2019-11-12 Amunix Pharmaceuticals Inc Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
AU2010313456A1 (en) 2009-10-30 2012-05-17 Ntf Therapeutics, Inc. Improved neurturin molecules
SI3564260T1 (sl) 2012-02-15 2023-02-28 Bioverativ Therapeutics Inc. Sestavki faktorja VIII in postopki njegove izdelave in uporabe
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
CN106519205B (zh) * 2016-10-26 2018-04-10 河南工程学院 一种载药多孔phbv接枝多巴胺微球的制备方法及应用
DK3576771T3 (da) 2017-01-31 2022-05-30 Veru Inc Sammensætninger og fremgangsmåder til langvarig frigivelse af antagonister for gonadotropin-frigivende hormon (gnrh)
CN110997693A (zh) 2017-06-07 2020-04-10 阿德克斯公司 τ聚集抑制剂
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS6048923A (ja) 1983-08-25 1985-03-16 Mitsui Toatsu Chem Inc 微小粒子の製造方法
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4882686A (en) * 1987-06-22 1989-11-21 Eastman Kodak Company Printing apparatus with improved data formatting circuitry
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
DK0478671T3 (da) 1989-06-21 1993-10-18 Univ Brown Res Found Neurologisk terapeutisk anordning
CH679207A5 (da) 1989-07-28 1992-01-15 Debiopharm Sa
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
JP3187410B2 (ja) 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤
JP3359919B2 (ja) 1990-05-16 2002-12-24 サザン・リサーチ・インスティテュート 放出制御ドーパミンおよび神経線維成長を刺激するための用途

Also Published As

Publication number Publication date
US6565875B2 (en) 2003-05-20
EP0767634B1 (en) 2004-03-10
ATE261278T1 (de) 2004-03-15
JPH10506373A (ja) 1998-06-23
EP0767634A1 (en) 1997-04-16
WO1996000537A1 (en) 1996-01-11
EP0767634A4 (en) 1998-09-30
DE69532673T2 (de) 2005-02-17
DE69532673D1 (de) 2004-04-15
US6517859B1 (en) 2003-02-11
ES2217281T3 (es) 2004-11-01
US20020094347A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
DK0767634T3 (da) Mikrokapsler til administration af neuroaktive midler
DE69133136T2 (de) Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
CA2182228A1 (en) Codrugs as a method of controlled drug delivery
ES2161366T3 (es) Composicion para la liberacion sostenida de hormona de crecimiento humana.
CA2198245A1 (en) Methods and means for drug administration
CA2187353A1 (en) Liquid delivery compositions
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
MX9709699A (es) Composicion para la liberacion sostenida de eritropoyetina no agregada.
EP0671162A3 (en) Amphoteric compositions and polymer forms of alpha-hydroxy acids, and their therapeutic use.
DE3778244D1 (de) Oestradiol-implantat und verfahren zu seiner herstellung.
DE69434963D1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
MX9603489A (es) Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos.
MXPA02012075A (es) Composicion para mediar el dolor y aparato y metodo para utilizarla.
AU2173400A (en) Method for administering agents to the central nervous system
DE69013797D1 (de) Gehirnspezifische Zubereitung mit gesteuerter Abgabe.
GB9212308D0 (en) Therapeutic compositions
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
GB9506796D0 (en) Device
DE69737296D1 (de) Synthetische antisense oligodeoxynukleotide und diese enthaltende pharmazeutische zusammensetzungen
GT199700096A (es) Ligandos espirociclos de un subtipo de receptor de la dopamina.
ATE257727T1 (de) Zusammensetzung und system zur iontophoretischen transdermalen abgabe von medikamenten
BR0213634A (pt) Sistema de liberação de droga com ação retardada para um agente antiespasmódico
DE69803607T2 (de) Zusammensetzungen zur transdermalen und dermalen verabreichung von biologisch wirksamen stoffen